{"id":744899,"date":"2014-11-16T04:25:00","date_gmt":"2014-11-16T04:25:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/"},"modified":"2023-03-22T00:04:48","modified_gmt":"2023-03-22T04:04:48","slug":"merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/","title":{"rendered":"Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma"},"content":{"rendered":"<p class=\"bwalignc\">       KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary        Endpoint of Progression-Free Survival     <\/p>\n<p class=\"bwalignc\">       Findings Presented for First Time at Society of Melanoma Research        (SMR) 2014 International Congress     <\/p>\n<p>ZURICH&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that a pre-specified analysis of investigational data<br \/>\n      from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA\u00ae<br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, substantially improved<br \/>\n      the primary endpoint of progression-free survival (PFS, as assessed by<br \/>\n      RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg\/kg<br \/>\n      and 10 mg\/kg every three week doses, respectively), compared to<br \/>\n      chemotherapy (P&lt;0.0001 for both comparisons) in patients with<br \/>\n      ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS<br \/>\n      rates for KEYTRUDA were 34 percent at the 2 mg\/kg dose (95% CI, 27-41)<br \/>\n      (n=180) and 38 percent at the 10 mg\/kg dose (95% CI, 31-45) (n=181),<br \/>\n      compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The<br \/>\n      median duration of follow-up at the interim analysis was 10 months.\n    <\/p>\n<p>\n      These findings, including pre-specified analyses of overall response<br \/>\n      rate (ORR), duration of response, safety and health-related quality of<br \/>\n      life (HRQoL), were presented today in an oral session by Dr. Antoni<br \/>\n      Ribas, professor, Hematology\/Oncology and Surgery, and director of the<br \/>\n      Tumor Immunology Program at the Jonsson Comprehensive Cancer Center,<br \/>\n      University of California, Los Angeles at the Society of Melanoma<br \/>\n      Research (SMR) 2014 International Congress in Zurich, Switzerland.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg every<br \/>\n      three weeks for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma and disease progression following ipilimumab and, if<br \/>\n      BRAF V600 mutation positive, a BRAF inhibitor. This indication is<br \/>\n      approved under accelerated approval based on tumor response rate and<br \/>\n      durability of response. An improvement in survival or disease-related<br \/>\n      symptoms has not yet been established. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      \u201cThese findings demonstrate KEYTRUDA was superior to chemotherapy in<br \/>\n      helping more patients with ipilimumab-refractory advanced melanoma<br \/>\n      achieve progression-free survival,\u201d said Dr. Eric Rubin, vice president,<br \/>\n      global clinical development for oncology, Merck Research Laboratories.<br \/>\n      \u201cThe comparative efficacy and safety data from the pivotal KEYNOTE-002<br \/>\n      study validate and extend the findings from our earlier study in these<br \/>\n      difficult-to-treat patients, and we look forward to sharing data on<br \/>\n      overall survival at a future congress.\u201d\n    <\/p>\n<p>\n      For the pre-specified analysis of PFS, no significant differences were<br \/>\n      observed between KEYTRUDA doses (HR 0.91, range 0.71-1.16) (P&lt;0.44). An<br \/>\n      assessment of PFS by investigator review was shown to be consistent with<br \/>\n      the central review findings. In addition, the PFS effect in favor of<br \/>\n      KEYTRUDA was consistent across all pre-specified sub-groups.\n    <\/p>\n<p>\n      The objective of the pre-specified analysis was to evaluate the<br \/>\n      superiority of either dose of KEYTRUDA over chemotherapy for PFS<br \/>\n      (conducted after \u2265 270 PFS events at a 0.25% significance level)<br \/>\n      (one-sided) (estimated HR, 0.66). The study was designed with co-primary<br \/>\n      endpoints of PFS and overall survival. An evaluation of overall survival<br \/>\n      is planned at the pre-specified final analysis in 2015.\n    <\/p>\n<p>\n      <b>Additional Efficacy Data and Safety from the KEYNOTE-002 Study<\/b>\n    <\/p>\n<p>\n      Overall response rates (confirmed) for KEYTRUDA were five to six times<br \/>\n      higher compared to chemotherapy. For KEYTRUDA, ORR was 21 percent at 2<br \/>\n      mg\/kg dose (95% CI, 15-28) and 25 percent at 10 mg\/kg dose (95% CI,<br \/>\n      19-32), compared to 4 percent for chemotherapy (95% CI, 2-9) (P&lt;0.0001<br \/>\n      for both comparisons). At the time of pre-specified analysis, the median<br \/>\n      duration of response for KEYTRUDA was not reached, and confirmed<br \/>\n      responses were ongoing in 92 percent of patients receiving 2 mg\/kg dose<br \/>\n      (range 6+ to 50+) and 87 percent receiving 10 mg\/kg dose (range 5+ to<br \/>\n      48+), respectively. The median duration of response was 37 weeks for<br \/>\n      chemotherapy arm and 63 percent of responses were ongoing (range 7+ to<br \/>\n      41). There was no significant difference in ORR or duration of response<br \/>\n      between the doses of KEYTRUDA (P=0.21).\n    <\/p>\n<p>\n      In a pre-specified exploratory analysis for HRQoL, patients treated with<br \/>\n      KEYTRUDA reported a significantly smaller decrement in health<br \/>\n      status\/quality of life score compared to those treated with chemotherapy<br \/>\n      (based on European Organization for Research and Treatment of Cancer<br \/>\n      (EORTC) Core Quality of Life Questionnaire or \u201cEORTC QLQ-C30\u201d). The mean<br \/>\n      change from baseline at week 12 (difference in least squares) for<br \/>\n      KEYTRUDA compared to chemotherapy was 6.52 (P=0.011) at 2 mg\/kg dose and<br \/>\n      6.57 (p=0.009) at 10 mg\/kg dose, respectively.\n    <\/p>\n<p>\n      The incidence of adverse events was consistent with previously reported<br \/>\n      data for KEYTRUDA. Despite longer median treatment duration, the<br \/>\n      incidence of treatment-related, grade 3-5 adverse events was lower with<br \/>\n      KEYTRUDA at 2 mg\/kg dose (11%) and at 10 mg\/kg dose (14%) compared to<br \/>\n      chemotherapy (26%). Serious treatment-related adverse events were<br \/>\n      observed for KEYTRUDA at 2 mg\/kg dose (8%) and 10 mg\/kg dose (11%), and<br \/>\n      for chemotherapy (10%). Immune-related grade 3 adverse events observed<br \/>\n      for KEYTRUDA across doses included hepatitis (n=3), colitis (n=2),<br \/>\n      pneumonitis (n=3), hypophysitis (n=1) and iritis or uveitis (n=1). No<br \/>\n      grade 4\/5 immune-related adverse events were reported. Three percent of<br \/>\n      patients receiving KEYTRUDA at 2 mg\/kg dose and 7 percent at the 10<br \/>\n      mg\/kg dose, as well as 6 percent receiving chemotherapy discontinued<br \/>\n      treatment due to investigator assessed, treatment-related adverse<br \/>\n      events. One treatment-related death was reported for KEYTRUDA and none<br \/>\n      in the chemotherapy arm.\n    <\/p>\n<p>\n      <b>About the KEYNOTE-002 Study<\/b>\n    <\/p>\n<p>\n      KEYNOTE-002 is a global, randomized pivotal Phase 2 study (n=540)<br \/>\n      evaluating KEYTRUDA at doses of 2 mg\/kg every three weeks (n=180) and<br \/>\n      10mg\/kg every three weeks (n=181) compared to investigator\u2019s choice<br \/>\n      chemotherapy (n=179) (paclitaxel plus carboplatin, paclitaxel,<br \/>\n      carboplatin, dacarbazine, or temozolomide) in patients with<br \/>\n      ipilimumab-refractory advanced melanoma. In the study, 83 percent of<br \/>\n      patients had the most advanced stage of disease (M1c) and 73 percent of<br \/>\n      patients had received at least two prior systemic therapies including<br \/>\n      ipilimumab. The co-primary endpoints were PFS and OS; secondary<br \/>\n      endpoints were ORR, duration of response and safety; and HRQoL as a<br \/>\n      pre-specified exploratory endpoint. Tumor response was assessed at week<br \/>\n      12, then every 6 weeks through week 48, followed by every 12 weeks<br \/>\n      thereafter by independent, central, blinded radiographic review per<br \/>\n      RECIST 1.1 (Response Evaluation Criteria in Solid Tumors). Patients on<br \/>\n      chemotherapy with progressive disease as assessed by blinded central<br \/>\n      review were able to cross over to KEYTRUDA arms after three months.\n    <\/p>\n<p>\n      <b>About KEYTRUDA (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA<br \/>\n      have not been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology is our focus to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=50984999&amp;newsitemid=20141116005033&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=da83b1816ac22048508a71fbd0604644\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=50984999&amp;newsitemid=20141116005033&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=a02ce3d1a05ef6855626d8768061c556\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=50984999&amp;newsitemid=20141116005033&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=ae2417282dcf3eab9cb2593c94a81dbb\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&amp;esheet=50984999&amp;newsitemid=20141116005033&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=50e237a8d41c3c06787ee7c7db8a67e7\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&amp;esheet=50984999&amp;newsitemid=20141116005033&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=5024ded66cb4091440b7ffc7748307e4\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50984999&amp;newsitemid=20141116005033&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=69f59456daf42da3653ead2672f2891f\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=50984999&amp;newsitemid=20141116005033&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=7&amp;md5=e7941acd87a0a8461b97d76928c02035\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=50984999&amp;newsitemid=20141116005033&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=8&amp;md5=ecc55eaa0bd0c6ec1b7448fa62742da9\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of Merck<br \/>\n      &amp; Co., Inc., Whitehouse Station, N.J., USA<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20141116005033r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Lainie Keller, 908-236-5036<br \/>Claire        Mulhearn, 908-236-1118<br \/>or<br \/>Investor:<br \/>Joseph Romanelli,        908-423-5185<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg\/kg and 10 mg\/kg every three week doses, respectively), compared to chemotherapy (P&lt;0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS rates for KEYTRUDA were 34 percent at the 2 mg\/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg\/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months. These findings, including pre-specified analyses of overall response rate (ORR), duration of response,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289,56],"class_list":["post-744899","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg\/kg and 10 mg\/kg every three week doses, respectively), compared to chemotherapy (P&lt;0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS rates for KEYTRUDA were 34 percent at the 2 mg\/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg\/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months. These findings, including pre-specified analyses of overall response rate (ORR), duration of response,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\\\/\",\"name\":\"Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-11-16T04:25:00+00:00\",\"dateModified\":\"2023-03-22T04:04:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg\/kg and 10 mg\/kg every three week doses, respectively), compared to chemotherapy (P&lt;0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540). At six months, the PFS rates for KEYTRUDA were 34 percent at the 2 mg\/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg\/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179). The median duration of follow-up at the interim analysis was 10 months. These findings, including pre-specified analyses of overall response rate (ORR), duration of response,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:48+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/","name":"Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-11-16T04:25:00+00:00","dateModified":"2023-03-22T04:04:48+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-positive-study-investigating-the-use-of-keytruda-pembrolizumab-compared-to-chemotherapy-in-patients-with-ipilimumab-refractory-advanced-melanoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Positive Study Investigating the Use of KEYTRUDA\u00ae (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a0a7e981-e308-4591-91e6-067e98488a14","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Positive-Study-Investigating-the-Use-of-KEYTRUDA-pembrolizumab-Compared-to-Chemotherapy-in-Patients-with-Ipilimumab-R-A1HPY.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744899\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744899"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}